Actively Recruiting
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
Led by University of California, Los Angeles · Updated on 2026-03-13
75
Participants Needed
1
Research Sites
295 weeks
Total Duration
On this page
Sponsors
U
University of California, Los Angeles
Lead Sponsor
B
Bausch & Lomb Incorporated
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.
CONDITIONS
Official Title
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Currently using one or more topical glaucoma antihypertensives
- Self-described symptoms of ocular surface discomfort
- Xiidra is being prescribed as part of the subject's standard care
You will not qualify if you...
- History of glaucoma filtration surgery or ocular surface surgery (such as pterygium or conjunctivoplasty)
- Current use of topical cyclosporine
- Current use of topical steroids
- Incisional ocular surgery within the past 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Doheny Eye Center UCLA
Fountain Valley, California, United States, 92708
Actively Recruiting
Research Team
B
Benjamin B Bert, MD
CONTACT
M
Mayra Raygoza
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here